Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Characteristics of the patients

From: Challenges in the implementation of a high-resolution anoscopy clinic for people with HIV in an oncologic center in Mexico City

 

N = 124

N (%)

Men* (n = 108)

Women* (n = 16)

Age in years, median (IQR)

38 (32–49)

36(31–44)

51 (39–54)

Age at onset of sexual life, median (IQR)

18 (16–19)

18 (16–19)

17 (15–19)

Number of sexual partners, median (IQR)

6 (3–10)

8 (4–10)

3 (2–4)

HIV diagnostic time in years, median (IQR)

5 (2–14)

4 (2–9)

17 (12–25)

Smoking history

72 (58)

67 (62)

5 (29)

Previous alcohol intake

21 (17)

20 (19)

1 (6)

Cancer diagnosis:

 Kaposi sarcoma

 Non-Hodgkin lymphoma

 Hodgkin lymphoma

 Invasive cervical cancer

 Other gynecological tumorsa

 Other cancers

 No cancer confirmation

80 (64)

13 (11)

7 (6)

3 (2)

8 (7)

4 (3)

9 (7)

80 (74)

11 (10)

7 (7)

0

0

2b (2)

8 (7)

0

2 (13)

0

3 (19)

8 (50)

2b (13)

1 (5)

Baseline CD4+ T cells/mm3, median (IQR)

97 (39–232)

84 (38–200)

213 (132–357)

Baseline HIV Viral load, log10 copies/mL

5.2 (4.6–5.7)

5.3 (4.7–5.7)

4.6 (4.1–5.6)

CD4+ T cells/mm3 count closest to the procedure, median (IQR)

331 (190–498)

307 (184–605)

498 (364–617)

ART at the moment of the procedure

123 (99)

107 (99)

16 (100)

  1. *Sex at birth
  2. aIncludes intraepithelial vulvar (3), vaginal (1), and cervical SIL lesions (4)
  3. bIncludes one multiple myeloma, one head and neck cancer, one breast cancer, and one skin cancer
  4. ART antiretroviral therapy